In a small randomized clinical trial of 15 adults with obsessive-compulsive disorder, psilocybin reduced OCD severity significantly more than an active placebo. After completing at least four high-dose sessions, nearly three-quarters of participants met criteria for treatment response, though researchers caution this is early-phase evidence from a very limited sample.

Key takeaways
  • Strong short-term signal: Research suggests that repeated high-dose psilocybin sessions reduced Yale-Brown Obsessive Compulsive Scale scores meaningfully, while lorazepam placebo did not produce the same effect.
  • Durable but fading benefit: Response rates remained substantial at six months, though the effect diminished over time, pointing to questions about maintenance dosing.
  • No serious harms detected: The trial reported no serious adverse events, no psychotic symptoms, and no significant shifts in suicide severity scores across the 15 participants.
  • Very early stage: With 15 participants across three arms, this Phase 1 study was designed to assess safety and tolerability first. Larger, adequately powered trials are needed before any conclusions about efficacy can be drawn.
Study at a glance
Model
human
Sample
15 adults with obsessive-compulsive disorder
Dose
High-dose psilocybin (300 micrograms per kilogram), low-dose (100 micrograms per kilogram), or active placebo (lorazepam); four weekly sessions in Phase 1, followed by four additional high-dose sessions in Phase 2
Design
Randomized, double-blind Phase 1 followed by single-blind Phase 2; 5 participants per condition in Phase 1
Key outcome
73.3% of participants who received at least four high-dose sessions met responder criteria (35% or greater reduction in YBOCS scores); effects diminished but remained substantial at 6 months
Main limitation
Very small sample (N=15), unequal phase designs, and absence of a full placebo-controlled Phase 2 limit interpretation of efficacy

What the Research Examined

This was a Phase 1 randomized clinical trial led by Moreno and colleagues, published in Journal of Psychopharmacology in 2026, investigating whether psilocybin could safely and meaningfully reduce symptoms in adults diagnosed with obsessive-compulsive disorder. Fifteen participants were divided into three groups of five: high-dose psilocybin (300 micrograms per kilogram), low-dose psilocybin (100 micrograms per kilogram), or an active placebo using lorazepam. All groups received four weekly sessions in a double-blind Phase 1, after which all participants crossed into a single-blind Phase 2 involving four additional high-dose psilocybin sessions. OCD severity was tracked using the Yale-Brown Obsessive Compulsive Scale, with follow-up extending to six months. You can read the full study at its published location in the Journal of Psychopharmacology.

The primary focus was safety and tolerability. Psilocybin was generally well-tolerated across all sessions: the trial recorded no serious adverse events, no psychotic episodes, and no clinically significant changes in suicide severity ratings. Only participants in the psilocybin arms, not those receiving lorazepam, showed meaningful reductions in YBOCS scores during Phase 1. After at least four cumulative high-dose sessions in Phase 2, 73.3% of the full sample qualified as treatment responders, meaning their YBOCS scores fell by 35% or more, and 40% met remission criteria. Those gains held at six months, though they had diminished from their peak.

For anyone wanting broader context on how this compound is being studied across conditions, our overview of psilocybin-assisted therapy research situates this OCD work within the wider clinical landscape. It is worth noting that a 2010 epidemiological study cited by the Psychology Today article reviewing these findings estimated the 12-month prevalence of OCD in the United States at around 1.2%, a modest figure that nonetheless represents a large number of people for whom existing treatments remain inadequate.

What the Findings Show

The measured results
  1. Responder rate after high-dose sessions.73.3% of participants (11 of 15) met the threshold for treatment response, defined as a 35% or greater reduction in Yale-Brown Obsessive Compulsive Scale total score, after completing at least four high-dose psilocybin sessions.
  2. Remission rate.40% of the full sample met remission criteria at the end of the eight-session treatment period.
  3. Six-month durability.Symptom reductions remained substantial at the six-month follow-up, though they had declined from their end-of-treatment peak, suggesting benefits may not be fully self-sustaining.
  4. Safety profile.No serious adverse events were recorded. There were no psychotic symptoms and no significant changes in suicide severity scores across all 15 participants throughout both phases of the trial.

A post-hoc analysis noted that cumulative dosing correlated with YBOCS score reductions, meaning participants who received more total high-dose sessions tended to show greater improvement. This is a hypothesis-generating observation from a very small sample, not a dose-response relationship that can be relied upon clinically. The absence of a full placebo-controlled Phase 2 is a meaningful limitation: once all participants moved into the open high-dose arm, the ability to separate drug effect from expectation effects diminished.

Does psilocybin reduce OCD symptoms in clinical trials?

In an early randomized trial of 15 adults, research suggests psilocybin reduced OCD severity significantly more than an active placebo, with nearly three-quarters of participants qualifying as responders after repeated high-dose sessions. These are promising preliminary findings, not established evidence of efficacy.

What This Is, and What It Is Not

Read this before you draw conclusions

This is This is a Phase 1 randomized clinical trial in 15 adults, designed primarily to evaluate safety and tolerability of repeated psilocybin doses in obsessive-compulsive disorder.

This is not This is not a large-scale efficacy trial, and the findings cannot be used to establish that psilocybin treats OCD. No one should alter a treatment plan based on this research. This content is educational, not medical advice.

Our Take

Within our community, we often speak of psilocybin as a sacrament that can dissolve the rigid thought loops the mind builds over a lifetime. It is striking, then, to watch the clinical literature begin to ask whether that same quality might offer something to people whose suffering is literally defined by loops they cannot stop. The OCD findings here are early and come from a small group, but they carry a kind of quiet coherence with what many in contemplative and ceremonial traditions have observed: that these experiences can loosen what is fixed. We hold that possibility with care and respect for the science that must now verify it rigorously.

An Invitation

Whether you arrived here through curiosity about the science, a personal struggle with intrusive thoughts, or a deepening relationship with this sacrament, you are welcome in this space. The research asks careful questions. Our community asks them alongside it. If you are in the early stages of understanding what psilocybin is and what it is not, we invite you to stay awhile, read slowly, and let the information settle, which is its own quiet form of Grounding before any path forward is chosen.

Source, Primary ResearchA randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorderMoreno FA et al. (2026). Journal of Psychopharmacology. DOI: 10.1177/02698811261424214.Read the original study

Frequently Asked Questions

How many psilocybin sessions were used in the OCD trial?

The trial used up to eight sessions total: four weekly sessions in a double-blind first phase, followed by four additional high-dose sessions in an open-label second phase. All sessions were conducted in a controlled clinical setting with monitoring.

What percentage of OCD participants responded to psilocybin?

After at least four high-dose psilocybin sessions, 73.3% of the 15 participants met the responder threshold of a 35% or greater reduction in Yale-Brown Obsessive Compulsive Scale scores. These are early-phase findings from a very small sample.

Was psilocybin safe in the OCD clinical trial?

In this small trial, psilocybin was generally well-tolerated. Researchers recorded no serious adverse events, no psychotic episodes, and no clinically significant increases in suicide severity across all participants and both phases of the study.

How long did psilocybin’s effects on OCD last?

Symptom reductions remained substantial at the six-month follow-up, but they had diminished from their end-of-treatment peak. Whether benefits can be maintained long-term, and what dosing schedule might support that, remains an open research question.

Is psilocybin an approved treatment for OCD?

No. Psilocybin is not approved for OCD or any other psychiatric condition. The research described here is an early-phase clinical trial. It is educational information only and should not be used to guide personal treatment decisions.

One study a day, plainly explained

Get the Mycelium Report

We read the new psilocybin and mushroom research so you do not have to. One honest, jargon-free dispatch, delivered daily. Free to join.

Join For Free

The Mycelium Report, Daily

May love guide the hearts of all beings.Doug Red Hail Pineda, Founder